These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 14534917)
1. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Findley L; Aujla M; Bain PG; Baker M; Beech C; Bowman C; Holmes J; Kingdom WK; MacMahon DG; Peto V; Playfer JR Mov Disord; 2003 Oct; 18(10):1139-45. PubMed ID: 14534917 [TBL] [Abstract][Full Text] [Related]
2. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Dodel RC; Singer M; Köhne-Volland R; Szucs T; Rathay B; Scholz E; Oertel WH Pharmacoeconomics; 1998 Sep; 14(3):299-312. PubMed ID: 10186468 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311 [TBL] [Abstract][Full Text] [Related]
4. A comparison of health-care costs involved in treating people with and without Parkinson's disease in Southern Sydney, New South Wales, Australia. Cordato DJ; Schwartz R; Abbott E; Saunders R; Morfis L J Clin Neurosci; 2006 Jul; 13(6):655-8. PubMed ID: 16797991 [TBL] [Abstract][Full Text] [Related]
5. [Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy]. Dodel RC; Pepperl S; Köhne-Volland R; Szucs T; Werhahn KJ; Noachtar S; Oertel WH Med Klin (Munich); 1996 Jul; 91(7):479-85. PubMed ID: 8756119 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667 [TBL] [Abstract][Full Text] [Related]
7. Cost of illness and its predictors for Parkinson's disease in Germany. Spottke AE; Reuter M; Machat O; Bornschein B; von Campenhausen S; Berger K; Koehne-Volland R; Rieke J; Simonow A; Brandstaedter D; Siebert U; Oertel WH; Ulm G; Dodel R Pharmacoeconomics; 2005; 23(8):817-36. PubMed ID: 16097843 [TBL] [Abstract][Full Text] [Related]
8. [Impact of motor and non-motor symptoms on the direct costs of Parkinson's disease]. Cubo E; Martínez Martin P; González M; Frades B; Neurologia; 2009; 24(1):15-23. PubMed ID: 19003550 [TBL] [Abstract][Full Text] [Related]
9. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Hagell P; Nordling S; Reimer J; Grabowski M; Persson U Mov Disord; 2002 Nov; 17(6):1213-20. PubMed ID: 12465059 [TBL] [Abstract][Full Text] [Related]
10. [Cost of illness and health service patterns in Morbus Parkinson in Austria]. von Campenhausen S; Winter Y; Gasser J; Seppi K; Reese JP; Pfeiffer KP; Geiger-Gritsch S; Bötzel K; Siebert U; Oertel WH; Dodel R; Poewe W Wien Klin Wochenschr; 2009; 121(17-18):574-82. PubMed ID: 19890747 [TBL] [Abstract][Full Text] [Related]
11. Costs of dialysis for elderly people in the UK. Grun RP; Constantinovici N; Normand C; Lamping DL; Nephrol Dial Transplant; 2003 Oct; 18(10):2122-7. PubMed ID: 13679490 [TBL] [Abstract][Full Text] [Related]
13. [Prospective study of the direct and indirect costs of idiopathic Parkinson's disease]. Dengler I; Leukel N; Meuser T; Jost WH Nervenarzt; 2006 Oct; 77(10):1204-9. PubMed ID: 17004081 [TBL] [Abstract][Full Text] [Related]
14. Short- and long-term cost and utilization of health care resources in Parkinson's disease in the UK. Weir S; Samnaliev M; Kuo TC; Tierney TS; Walleser Autiero S; Taylor RS; Schrag A Mov Disord; 2018 Jul; 33(6):974-981. PubMed ID: 29603405 [TBL] [Abstract][Full Text] [Related]
15. The current and projected economic burden of Parkinson's disease in the United States. Kowal SL; Dall TM; Chakrabarti R; Storm MV; Jain A Mov Disord; 2013 Mar; 28(3):311-8. PubMed ID: 23436720 [TBL] [Abstract][Full Text] [Related]
16. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China. Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620 [TBL] [Abstract][Full Text] [Related]
17. Costs of Parkinson's disease in eastern Europe: a Czech cohort study. Winter Y; von Campenhausen S; Brozova H; Skoupa J; Reese JP; Bötzel K; Eggert K; Oertel WH; Dodel R; Ruzicka E Parkinsonism Relat Disord; 2010 Jan; 16(1):51-6. PubMed ID: 19665915 [TBL] [Abstract][Full Text] [Related]
18. Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome. Callaghan R; Prabu A; Allan RB; Clarke AE; Sutcliffe N; Pierre YS; Gordon C; Bowman SJ; Rheumatology (Oxford); 2007 Jan; 46(1):105-11. PubMed ID: 16728437 [TBL] [Abstract][Full Text] [Related]
20. An economic model of Parkinson's disease: implications for slowing progression in the United States. Johnson SJ; Diener MD; Kaltenboeck A; Birnbaum HG; Siderowf AD Mov Disord; 2013 Mar; 28(3):319-26. PubMed ID: 23404374 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]